Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events.

Institut National de la Santé et de la Recherche Médicale, U875 (Biostatistique), Bordeaux, F-33076, France Bordeaux, F-33076, France.
Biostatistics (Impact Factor: 2.24). 11/2007; 8(4):708-21. DOI: 10.1093/biostatistics/kxl043
Source: PubMed

ABSTRACT The observation of repeated events for subjects in cohort studies could be terminated by loss to follow-up, end of study, or a major failure event such as death. In this context, the major failure event could be correlated with recurrent events, and the usual assumption of noninformative censoring of the recurrent event process by death, required by most statistical analyses, can be violated. Recently, joint modeling for 2 survival processes has received considerable attention because it makes it possible to study the joint evolution over time of 2 processes and gives unbiased and efficient parameters. The most commonly used estimation procedure in the joint models for survival events is the expectation maximization algorithm. We show how maximum penalized likelihood estimation can be applied to nonparametric estimation of the continuous hazard functions in a general joint frailty model with right censoring and delayed entry. The simulation study demonstrates that this semiparametric approach yields satisfactory results in this complex setting. As an illustration, such an approach is applied to a prospective cohort with recurrent events of follicular lymphomas, jointly modeled with death.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Identification of heart failure (HF) patients at risk for hospitalization may improve care and reduce costs. We evaluated nine biomarkers as predictors of cardiac hospitalization in chronic HF.
    Journal of Cardiac Failure 06/2014; · 3.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Frailty models are extensions of the Cox proportional hazards model which is the most pop-ular model in survival analysis. In many clinical applications, the study population needs to be considered as a heterogeneous sample or as a cluster of homogeneous groups of individuals such as families or geographical areas. Sometimes, due to lack of knowledge or for economical reasons, some covariates related to the event of interest are not measured. The frailty approach is a statistical modelling method which aims to account for the heterogeneity caused by unmea-sured covariates. It does so by adding random effects which act multiplicatively on the hazard function. FrailtyPack is an R package 1 which allows to fit four types of frailty models, for left-truncated and right-censored data, adapted to most survival analysis issues. The aim of this talk is to present the new version of the R package FrailtyPack, which is available from the Comprehen-sive R Archive Network at, and the various new models proposed. It depends on the R survival package. 2 The initial version of this package 3 was proposed for a simple shared frailty model, and was developed for more general frailty models. 4 The shared frailty model 5 can be used, when observations are supposed to be clustered into groups. The nested frailty model 6 is most appropriate, when there are two levels of hierarchical clustering. However, several relapses (recurrent events) are likely to increase the risk of death, thus the terminal event is considered as an informative censoring. Using a joint frailty model, it is possi-ble to fit jointly the two hazard functions associated with recurrent and terminal events, 7 when these events are supposed to be correlated. The additive frailty model 8 is more adapted to study both heterogeneity across trial and treatment-by-trial heterogeneity (for instance meta-analysis or multicentric datasets study). We show how a simple multi-state frailty model can be used to study semi-competing risks while fully taking into account the clustering (in ICU) of the data and the longitudinal aspects of the data, including left truncation and right censoring. 9 We included recently parametric hazard functions and prediction methods. Depending on the models, stratification and time-dependent covariates are allowed or not. The frailty models discussed in recent literature present several drawbacks. Their convergence is too slow, they do not provide standard errors for the variance estimate of the random ef-fects and they can not estimate smooth hazard function. FrailtyPack use a non-parametric penalized likelihood estimation, and the smooth estimation of the baseline hazard functions is provided by using an approximation by splines. FrailtyPack was first written in Fortran 77 and was implemented for the statistical software R. We will present the models that FrailtyPack can fit and the estimation method, then we will describe all the functions and the arguments of FrailtyPack. Finally epidemiological il-lustrations will be provided using FrailtyPack functions. FrailtyPack is improved regularly in order to add new developments around frailty models.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a typical randomized clinical study to compare a new treatment with a control, oftentimes each study subject may experience any of several distinct outcomes during the study period, which collectively define the "risk-benefit" profile. To assess the effect of treatment, it is desirable to utilize the entirety of such outcome information. The times to these events, however, may not be observed completely due to, for example, competing risks or administrative censoring. The standard analyses based on the time to the first event, or individual component analyses with respect to each event time, are not ideal. In this paper, we classify each patient's risk-benefit profile, by considering all event times during follow-up, into several clinically meaningful ordinal categories. We first show how to make inferences for the treatment difference in a two-sample setting where categorical data are incomplete due to censoring. We then present a systematic procedure to identify patients who would benefit from a specific treatment using baseline covariate information. To obtain a valid and efficient system for personalized medicine, we utilize a cross-validation method for model building and evaluation and then make inferences using the final selected prediction procedure with an independent data set. The proposal is illustrated with the data from a clinical trial to evaluate a beta-blocker for treating chronic heart failure patients.
    Biostatistics 08/2014; · 2.24 Impact Factor


Available from
May 23, 2014